Project Grant R01CA303847
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $694K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Irwindale, CA 91010, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $733,864 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Beckman Research Institute of the City of Hope, effective June 1, 2026, through May 31, 2031. This five-year research initiative focuses on identifying and characterizing stimulatory immune checkpoints that regulate macrophage-mediated programmed cell removal (PRCR) in tumor immunosurveillance. Using high-throughput CRISPR-based screening...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Beckman Research Institute of the City of Hope a $702,495 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2030. This research initiative focuses on developing novel therapeutic approaches to treat T cell lymphomas (TCLs), a highly heterogeneous group of lymphoid malignancies representing approximately 12% of all non-Hodgkin lymphomas. The project...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the Beckman Research Institute of the City of Hope a $517,090 Project Grant under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, to investigate the role and biological function of a novel signature gene designated AL021978.1 (A978) in Philadelphia chromosome (PH)-positive and PH-like B-cell acute lymphoblastic leukemia (B-ALL). The research aims to address high-risk leukemia subtypes with survival...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $457,683 to the Beckman Research Institute of the City of Hope to develop and evaluate novel "Bio-Beacons" - tumor-targeting bacterial vectors engineered to secrete chemokines and cytokines. The goal is to increase the density of tumor-reactive immune cells, such as CD8 T cells, CD4 T cells, dendritic cells, and natural killer cells, within solid tumors. This is...
- Federal Grant Award Summary The National Cancer Institute awarded $178,000 to the Beckman Research Institute of the City of Hope under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for a Project Grant commencing June 23, 2025, with a completion date of May 31, 2027. The research focuses on evaluating the ELF5 (E74-like factor 5) clock as a novel biomarker for breast cancer prevention clinical trials. The ELF5 clock is a breast-specific biological aging measurement tool that...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $677,787 to The Regents of the University of California, San Francisco on August 26, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award supports a five-year research initiative (through July 31, 2030) investigating AIRE-expressing tumor-associated macrophages (AIRE+ TAMs) as novel mediators of tumor immune evasion. The research aims to characterize the molecular and...
- Federal Project Grant Award Summary The Beckman Research Institute of the City of Hope received a $966,220 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective September 1, 2025 through August 31, 2030. This award supports fundamental research investigating the functional role of PAX5 (Paired Box 5) mutations in B-cell acute lymphoblastic leukemia (B-ALL), the most common pediatric cancer. The research will dissect the mechanisms...
- Federal Grant Award Summary The National Cancer Institute awarded a Project Grant totaling $648,626 to the University of California, Irvine under the Cancer Treatment Research program (CFDA 93.395) on April 2, 2026, with a completion date of March 31, 2031. This award funds research investigating the mechanisms of immunosuppression triggered by checkpoint blockade immunotherapy (CBI), specifically examining how PD-1 (Programmed Death-1) inhibition affects tumor-infiltrating regulatory T cells...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
- Federal Grant Award Summary The National Cancer Institute awarded a $710,361 Project Grant under the Cancer Biology Research program (CFDA 93.396) to J. David Gladstone Institutes, effective August 1, 2025, through May 31, 2030. This award funds the development of a spatial profiling-based immune hub perturbation platform designed to improve immunotherapy efficacy in colorectal cancer (CRC). The research addresses a critical gap in preclinical modeling by creating experimental frameworks that...